Medicines & Healthcare products Regulatory Agency

MHRA Central Freedom of Information Team
10 South Colonnade
Canary Wharf
London
E14 4PU

foi.request@mhra.gov.uk.

MHRA Website

[redacted]

Our Ref: **FOI2026/00052**

6 February 2026

Dear [redacted]

Thank you for your Freedom of Information (FOI) request received on 19 January. You wrote:

> *Dear Medicines and Healthcare Products Regulatory Agency, would you please provide me with all reports in which there was one event (MedDRA PT) from the Embolism and thrombosis HGLT (Vascular disorders SOC) and the PT of thrombocytopenia (Blood and lymphatic system disorders SOC) OR the PT of platelet count decreased (investigations SOC) OR platelet count abnormal (Investigations SOC).*
>
> *To be clear this request relates to event reports following exposure to Covid-19 AstraZeneca Vaccine (AZD1222/ChAdOx1-S) Vaxrevia - during the period of its licensing (2021-2024).*

MHRA Response

We can confirm that the Agency holds this information. However, the information is exempt under Section 21(1) of the Freedom of Information Act because the information is reasonably accessible to you, as it is already in the public domain.

The data published by the MHRA on the suspected side effects reported for the AstraZeneca vaccine can be found in the interactive Drug Analysis Profile (iDAP) at the link below:

https://yellowcard.mhra.gov.uk/idaps/CHADOX1%20NCOV-19

This contains a complete listing of all suspected adverse reactions that have been reported to the MHRA via the Yellow Card scheme. On the iDAP you can view the types of reactions that have been reported on the Total Reaction Profile tab. You may also use the filters on the left-hand side of the page to view the specific information you require.

It is important to note that the information presented in the iDAPs does not represent an overview of the potential side effects associated with the product. A list of the recognised suspected adverse reactions is provided in the information for healthcare professionals and the PILs which can be found here:
Find product information about medicines - GOV.UK

When considering this spontaneous ADR data, it is important to be aware of the following points:

- A reported reaction, including those with a fatal outcome, does not necessarily mean it has been caused by a medicine, only that the reporter had a suspicion it may have been. The fact that symptoms occur after use of a medicine, and are reported via the Yellow Card scheme, does not in itself mean that they are proven to have been caused by it. Underlying or concurrent illnesses may be responsible and such events can also be coincidental.

- It is also important to note that the number of reports received via the Yellow Card scheme does not directly equate to the number of people who suffer adverse reactions and therefore cannot be used to determine the incidence of a reaction. ADR reporting rates are influenced by the seriousness of ADRs, their ease of recognition, the extent of use of a particular medicine or vaccine and may be stimulated by promotion and publicity about a medicine or vaccine. For these reasons the enclosed data should not be used as a basis for determining incidence of side effects.

- The MHRA continuously monitors the safety of medicines through a variety of pharmacovigilance processes, including the Yellow Card scheme. As part of our signal detection processes, all adverse reaction reports received by the Yellow Card scheme are assessed, and cumulative information is reviewed at regular intervals. If appropriate, regulatory action would be taken if any serious risks were confirmed.

If you have any queries about this letter, please contact us quoting the reference number above.

Yours sincerely,

MHRA Central Freedom of Information Team
Medicines & Healthcare products Regulatory Agency

Your right to complain under the Freedom of Information Act

If you are not happy with this response you may request an internal review by e-mailing foi.request@mhra.gov.uk or by writing to: MHRA Central Freedom of Information Team, 10 South, Colonnade, Canary Wharf, London, E14 4PU

Any request for an internal review must be received by us within 40 working days of the date of this letter. Please note we are not obliged to provide a review if it is requested after more than 40 working days.

If you are not content with the outcome of the internal review, you may apply directly to the Information Commissioner's Office for a decision. Generally, the Commissioner cannot make a decision unless you have exhausted our own complaints procedure. The Information Commissioner can be contacted at: The Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.
Website: ICO FOI and EIR complaints or telephone 0303 123 1113.

Re-use of our information
The MHRA information supplied in response to your request is subject to Crown copyright. Information created by the MHRA which is disclosed under the Freedom of Information Act is made available for re-use under the Open Government Licence (OGL) v3.0, except where

this is otherwise stated. There are some restrictions on re-use under the OGL and these can be viewed here:
https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/